Clinical guidelines. Crohn’s disease (К50), adults

<jats:p>.</jats:p>

[1]  N. V. Kostenko,et al.  Consensus on controversial issues of the surgery for Crohn’s disease by Delphi method , 2023, Koloproktologia.

[2]  M. V. Zlobin,et al.  Clinical and Demographic Features and Treatment Approaches for Inflammatory Bowel Diseases (Crohn’s Disease, Ulcerative Colitis) in the Russia. The Primery Results of the Analysis of the National Register , 2023, Koloproktologia.

[3]  E. Chashkova,et al.  Clinical and epidemiological aspects of ulcerative colitis in the Irkutsk region , 2023, Koloproktologia.

[4]  S. Hosomi,et al.  Expert consensus on vaccination in patients with inflammatory bowel disease in Japan , 2023, Journal of Gastroenterology.

[5]  N. Humphry,et al.  The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance , 2022, EMJ Gastroenterology.

[6]  M. Regueiro,et al.  The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium , 2022, The American journal of gastroenterology.

[7]  Yi Ji,et al.  Efficacy and safety of FiLaC™ for perianal fistulizing Crohn’s disease: a systematic review and meta-analysis , 2022, Techniques in Coloproctology.

[8]  Ewa Małecka-Wojciesko,et al.  COVID-19 Vaccination in Inflammatory Bowel Disease (IBD) , 2022, Journal of clinical medicine.

[9]  S. Sebastian,et al.  Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis , 2022, Clinical Gastroenterology and Hepatology.

[10]  B. Antolin-Fontes,et al.  Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn’s Disease patients: A retrospective analysis using German claims data , 2022, Therapeutic advances in gastroenterology.

[11]  P. Kurki,et al.  Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective , 2021, Drugs.

[12]  S. Ng,et al.  International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease , 2021, Nature Reviews Gastroenterology & Hepatology.

[13]  P. Kamble,et al.  P267 Sequencing of anti-TNF agents and gut-selective anti-lymphocyte trafficking (GSALT) therapy in the treatment of Crohn’s disease (CD) , 2021 .

[14]  B. Boyle,et al.  Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money. , 2021, Inflammatory bowel diseases.

[15]  Siddharth Singh,et al.  Spotlight: Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. , 2021, Gastroenterology.

[16]  M. Silverberg,et al.  Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study , 2021, Journal of Crohn's & colitis.

[17]  M. Toruner,et al.  ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. , 2021, Journal of Crohn's & colitis.

[18]  A. Parfenov,et al.  [Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn's disease when switching from the original infliximab to its biosimilars]. , 2021, Terapevticheskii arkhiv.

[19]  A. V. van Bodegraven,et al.  Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. , 2021, Inflammatory bowel diseases.

[20]  M. Shapina,et al.  Risk factors for postoperative complications after surgery in complicated Crohn’s disease , 2021, Hirurg (Surgeon).

[21]  E. Savarino,et al.  Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study , 2021, Therapeutic advances in gastroenterology.

[22]  E. Savarino,et al.  A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study , 2021, Therapeutic advances in gastroenterology.

[23]  K. Stavem.  Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief review , 2021, Journal of market access & health policy.

[24]  A. Griffiths,et al.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. , 2020, Gastroenterology.

[25]  A. Moniuszko,et al.  Biosimilar infliximab versus originator in Crohn’s disease anti-TNF-α naïve and non-naïve patients , 2020, Przeglad gastroenterologiczny.

[26]  Weiming Zhu,et al.  Comparison of primary anastomosis and staged surgery in emergency treatment of complicated Crohn's disease , 2020, Journal of digestive diseases.

[27]  A. Lila,et al.  Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts’ opinion , 2020, Almanac of Clinical Medicine.

[28]  G. Rogler,et al.  Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease , 2020, Inflammatory bowel diseases.

[29]  D. D. de Jong,et al.  Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment , 2020, Alimentary pharmacology & therapeutics.

[30]  A. Amiot,et al.  The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor , 2020, Alimentary pharmacology & therapeutics.

[31]  S. Bonovas,et al.  Proactive TDM for Crohn's disease patients in clinical remission under anti-TNF treatment: current state of evidence. , 2020, Journal of Crohn's & colitis.

[32]  S. Ng,et al.  The epidemiology of inflammatory bowel disease: East meets west , 2019, Journal of gastroenterology and hepatology.

[33]  J. Lewis,et al.  Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. , 2020, Gastroenterology.

[34]  B. Flourié,et al.  Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial , 2020, Gut.

[35]  E. Arranz,et al.  P679 What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF? , 2020 .

[36]  S. Vermeire,et al.  Systematic review and external validation of prediction models based on symptoms and biomarkers for identifying endoscopic activity in Crohn's disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  L. Stassen,et al.  ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. , 2019, Journal of Crohn's & colitis.

[38]  M. Parkes,et al.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults , 2019, Gut.

[39]  J. Gisbert,et al.  Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. , 2019, Inflammatory bowel diseases.

[40]  M. Regueiro,et al.  Endoscopy in Postoperative Patients with Crohn's Disease or Ulcerative Colitis. Does It Translate to Better Outcomes? , 2019, Gastrointestinal endoscopy clinics of North America.

[41]  M. Gee,et al.  Performance of Surveillance MR Enterography (MRE) in Asymptomatic Children and Adolescents With Crohn's Disease , 2019, Journal of magnetic resonance imaging : JMRI.

[42]  D. Schwartz,et al.  Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn’s Disease: A Systematic Review , 2019, Digestive Diseases and Sciences.

[43]  T. Lu,et al.  Maneuvering Clinical Pathways for Crohn’s Disease , 2019, Current Gastroenterology Reports.

[44]  A. Ananthakrishnan,et al.  The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. , 2019, Gastrointestinal endoscopy clinics of North America.

[45]  J. Fletcher,et al.  Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review , 2019, Gut.

[46]  B. Long,et al.  Emergency Medicine Evaluation and Management of Small Bowel Obstruction: Evidence-Based Recommendations. , 2019, The Journal of emergency medicine.

[47]  C. Buskens,et al.  Systematic review and meta‐analysis of endorectal advancement flap and ligation of the intersphincteric fistula tract for cryptoglandular and Crohn's high perianal fistulas , 2019, BJS open.

[48]  S. Steele,et al.  Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis , 2018, International Journal of Colorectal Disease.

[49]  A. O. Golovenko,et al.  Social and demographic characteristics, features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies , 2018, Almanac of Clinical Medicine.

[50]  O. Faiz,et al.  Symptom Amelioration in Crohn’s Perianal Fistulas Using Video-Assisted Anal Fistula Treatment (VAAFT) , 2018, Journal of Crohn's & colitis.

[51]  P. Moayyedi,et al.  Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. , 2018, Inflammatory bowel diseases.

[52]  D. Turner,et al.  Antibiotics in IBD: Still a Role in the Biological Era? , 2018, Inflammatory bowel diseases.

[53]  I. Khalif,et al.  THE EFFICIENCY OF POSTOPERATIVE PREVENTIVE TREATMENT BY ADALIMUMAB AND AZATHIOPRINE IN CROHN'S DISEASE , 2018, Koloproktologia.

[54]  M. Murad,et al.  Systematic review and network meta‐analysis: first‐ and second‐line biologic therapies for moderate‐severe Crohn's disease , 2018, Alimentary pharmacology & therapeutics.

[55]  L. M. Wong Kee Song,et al.  Outcomes of Endoscopic Therapy for Luminal Strictures in Crohn's Disease. , 2018, Inflammatory bowel diseases.

[56]  J. Colombel,et al.  Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease , 2018, Journal of Crohn's & colitis.

[57]  M. Regueiro,et al.  ACG Clinical Guideline: Management of Crohn’s Disease in Adults , 2018, The American Journal of Gastroenterology.

[58]  N. Hyman,et al.  Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn’s Disease , 2018, Journal of Crohn's & colitis.

[59]  Hillel P. Cohen,et al.  Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes , 2018, Drugs.

[60]  E. Loftus,et al.  Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations , 2018, Alimentary pharmacology & therapeutics.

[61]  K. Umanskiy,et al.  The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. , 2018, Inflammatory bowel diseases.

[62]  C. Buskens,et al.  Persistent Mesorectal Inflammatory Activity is Associated With Complications After Proctectomy in Crohn’s Disease , 2018, Journal of Crohn's & colitis.

[63]  I. Khalif,et al.  POSTOPERATIVE PREVENTIVE TREATMENT OF CROHN'S DISEASE (review) , 2017 .

[64]  C. Buskens,et al.  ECCO-ESCP Consensus on Surgery for Crohn's Disease. , 2017, Journal of Crohn's & colitis.

[65]  G. Kaplan,et al.  Systematic review with meta‐analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials , 2017, Alimentary pharmacology & therapeutics.

[66]  W. Bemelman,et al.  Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls , 2017, Intestinal research.

[67]  J. Fletcher,et al.  MR Imaging of Perianal Crohn Disease. , 2017, Radiology.

[68]  C. Buskens,et al.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. , 2017, Journal of Crohn's & colitis.

[69]  M. Olandoski,et al.  Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn’s Disease , 2017, Digestive Diseases and Sciences.

[70]  Harry Sokol,et al.  A microbial signature for Crohn's disease , 2017, Gut.

[71]  P. Rutgeerts,et al.  Responsiveness of Endoscopic Indices of Disease Activity for Crohn’s Disease , 2017, The American Journal of Gastroenterology.

[72]  L. Skov,et al.  Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study , 2016, The British journal of dermatology.

[73]  U. Navaneethan,et al.  Endoscopic balloon dilation in the management of strictures in Crohn’s disease: a systematic review and meta-analysis of non-randomized trials , 2016, Surgical Endoscopy.

[74]  K. Tandon,et al.  Crohn's disease presenting as acute gastrointestinal hemorrhage. , 2016, World journal of gastroenterology.

[75]  H. Tilg,et al.  The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[76]  J. Burke,et al.  A Meta-analysis of Percutaneous Drainage Versus Surgery as the Initial Treatment of Crohn's Disease-related Intra-abdominal Abscess. , 2016, Journal of Crohn's & colitis.

[77]  A. Reginelli,et al.  3D-EAUS and MRI in the Activity of Anal Fistulas in Crohn's Disease , 2015, Gastroenterology research and practice.

[78]  W. Sandborn,et al.  Systematic review with meta‐analysis: faecal diversion for management of perianal Crohn's disease , 2015, Alimentary pharmacology & therapeutics.

[79]  T. Murdoch,et al.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.

[80]  D. Schwartz,et al.  Imaging of perianal fistulizing Crohn’s disease , 2015, Expert review of gastroenterology & hepatology.

[81]  Jacob E. Kurlander,et al.  A Meta-Analysis of the Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin, and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS , 2015, The American Journal of Gastroenterology.

[82]  J. Gisbert,et al.  European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. , 2015, Journal of Crohn's & colitis.

[83]  G. Kaplan,et al.  Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. , 2015, Gastroenterology.

[84]  Helmut Neumann,et al.  Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. , 2015, World journal of gastroenterology.

[85]  C. Lees,et al.  Clinical Utility And Diagnostic Accuracy of Faecal Calprotectin For IBD At First Presentation To Gastroenterology Services In Adults Aged 16–50 Years , 2014, Journal of Crohn's & colitis.

[86]  W. Bemelman,et al.  A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease , 2014, Gut.

[87]  P. Malfertheiner,et al.  Double‐balloon enteroscopy in the diagnosis of suspected isolated Crohn's disease of the small bowel , 2014, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[88]  A. Bousvaros,et al.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  A. Ford,et al.  Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. , 2013, Journal of Crohn's & colitis.

[90]  E. Savarino,et al.  Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial , 2013, The American Journal of Gastroenterology.

[91]  G. Petris,et al.  European consensus on the histopathology of inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[92]  P. Kawalec,et al.  Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis , 2013, Archives of medical science : AMS.

[93]  Jeroen A. W. Tielbeek,et al.  Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. , 2013, Journal of Crohn's & colitis.

[94]  P. Lakatos,et al.  The burden of inflammatory bowel disease in Europe. , 2013, Journal of Crohn's & colitis.

[95]  F. Remzi,et al.  Crohn's disease complicated by strictures: a systematic review , 2013, Gut.

[96]  N. Pedersen,et al.  East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort , 2013, Gut.

[97]  D. Hommes,et al.  Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI) , 2013, Gut.

[98]  Tal Raphaeli,et al.  Current Treatment of Lower Gastrointestinal Hemorrhage , 2012, Clinics in Colon and Rectal Surgery.

[99]  J. Church,et al.  Biological immunomodulators improve the healing rate in surgically treated perianal Crohn’s fistulas , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[100]  G. Mantzaris,et al.  Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. , 2012, Journal of Crohn's & colitis.

[101]  H. Thorlacius,et al.  A unique 3D endoanal ultrasound feature of perianal Crohn’s fistula: the ‘Crohn ultrasound fistula sign’ , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[102]  J. Gisbert,et al.  Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.

[103]  J. Kjeldsen,et al.  Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon , 2011, Scandinavian journal of gastroenterology.

[104]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[105]  P. Moayyedi,et al.  Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[106]  P. Prandoni,et al.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score , 2010, Journal of thrombosis and haemostasis : JTH.

[107]  J. Ritz,et al.  Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn’s disease—review of the literature , 2010, International Journal of Colorectal Disease.

[108]  A. Hara,et al.  Capsule Endoscopy Has a Significantly Higher Diagnostic Yield in Patients With Suspected and Established Small-Bowel Crohn's Disease: A Meta-Analysis , 2010, The American Journal of Gastroenterology.

[109]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[110]  L. Laine,et al.  Cytomegalovirus Infection in Patients with Active Inflammatory Bowel Disease , 2010, Digestive Diseases and Sciences.

[111]  S. Hanauer,et al.  Azathioprine and 6-Mercaptopurine for the Prevention of Postoperative Recurrence in Crohn's Disease: A Meta-Analysis , 2009, The American Journal of Gastroenterology.

[112]  H. Tilg,et al.  Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.

[113]  K. Thakkar,et al.  Repeat Endoscopy Affects Patient Management in Pediatric Inflammatory Bowel Disease , 2009, The American Journal of Gastroenterology.

[114]  L. Martí-Bonmatí,et al.  Assessment of the extension and the inflammatory activity in Crohn’s disease: comparison of ultrasound and MRI , 2009, Abdominal Imaging.

[115]  M. Regueiro,et al.  Infliximab prevents Crohn's disease recurrence after ileal resection. , 2009, Gastroenterology.

[116]  R. Bleichrodt,et al.  Colectomy in Patients with Acute Colitis: A Systematic Review , 2009, Journal of Gastrointestinal Surgery.

[117]  A. Ananthakrishnan,et al.  Clostridium difficile and inflammatory bowel disease. , 2008, Inflammatory bowel diseases.

[118]  V. Fazio,et al.  Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn's disease: follow-up of a prospective randomized trial. , 2008, Surgery.

[119]  G. Kaplan,et al.  The Risk of Developing Crohn's Disease After an Appendectomy: A Meta-Analysis , 2008, The American Journal of Gastroenterology.

[120]  G. Kaplan,et al.  A National Survey of the Prevalence and Impact of Clostridium difficile Infection Among Hospitalized Inflammatory Bowel Disease Patients , 2008, The American Journal of Gastroenterology.

[121]  Roelof J Bennink,et al.  Magnetic resonance imaging in Crohn's disease , 2008 .

[122]  J. Belaiche,et al.  Predictors of severe Crohn's disease , 2008, Scandinavian journal of gastroenterology.

[123]  S. Purkayastha,et al.  Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short‐term outcomes and recurrence , 2007, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[124]  V. Fazio,et al.  Safety and Efficacy of Strictureplasty for Crohn’s Disease: A Systematic Review and Meta-Analysis , 2007, Diseases of the colon and rectum.

[125]  A. Darzi,et al.  A Meta-Analysis Comparing Conventional End-to-End Anastomosis vs. Other Anastomotic Configurations After Resection in Crohn’s Disease , 2007, Diseases of the colon and rectum.

[126]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[127]  G. Costamagna,et al.  Video Capsule Endoscopy in Patients With Known or Suspected Small Bowel Stricture Previously Tested With the Dissolving Patency Capsule , 2007, Journal of clinical gastroenterology.

[128]  M. Riccioni,et al.  Patients With Known Small Bowel Stricture or With Symptoms of Small Bowel Obstruction Secondary to Crohn's Disease Should Not Perform Video Capsule Endoscopy Without Being Previously Tested for Small Bowel Patency , 2007, The American Journal of Gastroenterology.

[129]  D. Martines,et al.  Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease , 2007, International Journal of Colorectal Disease.

[130]  Dawn B. Beaulieu,et al.  Impact of Clostridium difficile on inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[131]  Kimberly A. Reske,et al.  Incidence of Clostridium difficile infection in inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[132]  H. Drummond,et al.  The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5‐year UK inception cohort , 2006, Alimentary pharmacology & therapeutics.

[133]  A. Darzi,et al.  A comparison of segmental vs subtotal/total colectomy for colonic Crohn's disease: a meta‐analysis , 2006, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[134]  D. Gouma,et al.  Laparoscopic-Assisted Versus Open Ileocolic Resection for Crohn's Disease: A Randomized Trial , 2006, Annals of surgery.

[135]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[136]  G. Casazza,et al.  Role of US in detection of Crohn disease: meta-analysis. , 2005, Radiology.

[137]  C. Fagnani,et al.  Evolution of clinical behaviour in Crohn's disease: predictive factors of penetrating complications. , 2005, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[138]  M. Solomon,et al.  Long-Term Indwelling Seton for Complex Anal Fistulas in Crohn’s Disease , 2005, Diseases of the colon and rectum.

[139]  Paul Rutgeerts,et al.  C-Reactive Protein as a Marker for Inflammatory Bowel Disease , 2004, Inflammatory bowel diseases.

[140]  S. Travis,et al.  Guidelines for the management of inflammatory bowel disease in adults , 2004, Gut.

[141]  D. Rampton,et al.  Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool , 2004, European journal of gastroenterology & hepatology.

[142]  S. Somers,et al.  Prospective Comparison of Small Bowel Meal with Pneumocolon versus Ileo-Colonoscopy for the Diagnosis of Ileal Crohn's Disease , 2004, American Journal of Gastroenterology.

[143]  E. Loftus.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[144]  J. Stein,et al.  Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine , 2004, Alimentary pharmacology & therapeutics.

[145]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[146]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[147]  P. Rutgeerts,et al.  A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.

[148]  M. Keighley,et al.  Effect of Fecal Diversion Alone on Perianal Crohn's Disease , 2000, World Journal of Surgery.

[149]  J. Korzenik.  Massive lower gastrointestinal hemorrhage in Crohn’s disease , 2000, Current treatment options in gastroenterology.

[150]  A. Forbes,et al.  Intra‐abdominal and pelvic abscess in Crohn's disease: results of non‐invasive and surgical management , 1998, The British journal of surgery.

[151]  D. Cameron.  Upper and lower gastrointestinal endoscopy in children and adolescents with Crohn's disease: A prospective study , 1991, Journal of gastroenterology and hepatology.

[152]  P. Rutgeerts,et al.  Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.

[153]  G. Ghahremani,et al.  Appendicitis as the initial manifestation of Crohn's disease: radiologic features and prognosis. , 1987, AJR. American journal of roentgenology.

[154]  E. Lubbers,et al.  Perianal fistulas in patients with Crohn's disease. , 1986, Archives of surgery.

[155]  K. Ewe,et al.  European cooperative Crohn's disease study (ECCDS) : Results of drug treatment , 1984 .

[156]  M. Ferrante,et al.  ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. , 2017, Journal of Crohn's & colitis.

[157]  H. Tilg,et al.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management , 2017, Journal of Crohn's & colitis.

[158]  R. Gullo,et al.  Large retroperitoneal abscess extended to the inferior right limb secondary to a perforated ileal Crohn's disease: the importance of the multidisciplinary approach. , 2016, Il Giornale di chirurgia.

[159]  C. Fiocchi,et al.  Immunopathogenesis of IBD: current state of the art , 2016, Nature Reviews Gastroenterology &Hepatology.

[160]  I. Khalif,et al.  CERTOLIZUMAB PEGOL IN CHOHN'S DISEASE (review) , 2016 .

[161]  Takayuki Yamamoto.  Prevention of Postoperative Recurrence in Crohn’s Disease , 2014, Drugs.

[162]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.